0001906324-24-000002.txt : 20240213 0001906324-24-000002.hdr.sgml : 20240213 20240213160722 ACCESSION NUMBER: 0001906324-24-000002 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240213 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 FILER: COMPANY DATA: COMPANY CONFORMED NAME: QuidelOrtho Corp CENTRAL INDEX KEY: 0001906324 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 874496285 FISCAL YEAR END: 0101 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41409 FILM NUMBER: 24625829 BUSINESS ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 552-1100 MAIL ADDRESS: STREET 1: 9975 SUMMERS RIDGE ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Coronado Topco, Inc. DATE OF NAME CHANGE: 20220124 8-K 1 qdel-20240213.htm 8-K qdel-20240213
0001906324false00019063242024-02-132024-02-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 13, 2024

QUIDELORTHO CORPORATION
(Exact name of Registrant as specified in its Charter)

Delaware
001-41409

87-4496285
 (State or other jurisdiction of incorporation)
 (Commission File Number)
 (IRS Employer Identification No.)

9975 Summers Ridge Road, San Diego, California 92121
(Address of principal executive offices, including zip code)
(858552-1100
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act if 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 2.02    Results of Operations and Financial Condition.

On February 13, 2024, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its fourth quarter and full year ended December 31, 2023 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on February 13, 2024 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.

The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01    Financial Statements and Exhibits.
 (d)    Exhibits.
 The following exhibit is furnished with this Form 8-K:
  
Exhibit NumberDescription of Exhibit
99.1
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 13, 2024
   
QUIDELORTHO CORPORATION
  
By:/s/ Joseph M. Busky 
Name:Joseph M. Busky 
Its:Chief Financial Officer 


EX-99.1 2 qdel12312023ex991earningsr.htm EX-99.1 Document
Exhibit 99.1

qographic.jpg

February 13, 2024

QuidelOrtho Reports Fourth Quarter and Full-Year 2023
Financial Results
Strong momentum in Labs business, with solid non-respiratory business growth and
market share gains in industry-leading respiratory point-of-care portfolio

Fourth Quarter 2023 Results and Highlights

Revenue was $743 million, as reported:
Non-respiratory revenue increased by 9% as reported and in constant currency
Respiratory revenue decreased by 49% as reported and in constant currency
GAAP net cash provided by operating activities was $80 million; adjusted free cash flow was $89 million
Received 510(k) clearance for Savanna multiplex molecular platform and HSV/VZV PCR assay
Received CLIA waiver for Sofia® 2 SARS Antigen+ FIA

Full-Year 2023 Results and Highlights

Revenue was $3.0 billion, as reported:
Non-respiratory revenue increased by 61% as reported (largely driven by the Combinations); supplemental combined non-respiratory revenue increased by 5% in constant currency
Respiratory revenue decreased by 61% as reported; supplemental combined respiratory revenue decreased by 62% in constant currency
GAAP net cash provided by operating activities was $280 million; adjusted free cash flow was $270 million
Paid down $227 million in term loan debt and completed $7 million in share repurchases
Received more than 700 regulatory clearances in U.S., EMEA and China

San Diego, CA — QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the fourth quarter and full-year ended December 31, 2023.

“In our first full year operating as a combined company, we successfully laid the foundation for building a broader-based diagnostics company poised for future growth. We are encouraged by the growth in our non-respiratory business, the market share gains we are seeing in our respiratory portfolios, and the U.S. launch of our Savanna molecular platform. Our competitive positions are strong across the globe, and we believe our pipeline of innovative new products and menu expansions will continue to strengthen pull-through across our growing installed base,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.

"We identified substantially greater synergies, while investing in the business and paying down debt. For example, we completed significant manufacturing upgrades to address instrument backlogs and meet market demand in our Labs business. In our Transfusion Medicine business, we are determined to continue investing in our Immunohematology portfolio and will begin winding down the U.S. Donor Screening portfolio,” he added.

“We have taken measures to reduce costs across the Company to lessen the impact of macro factors, such as inflation, the variability of the respiratory season and global supply chain constraints. Finally, we are accelerating our business efficiency initiatives, including our capital allocation strategy and portfolio management processes, to support durable long-term growth and generate shareholder value,” Bryant concluded.



qographic.jpg
Fourth Quarter 2023

The Company reported total revenue for the fourth quarter of 2023 of $743 million, compared to $867 million in the prior year period. Foreign currency translation did not significantly impact fourth quarter 2023 results. GAAP diluted EPS for the fourth quarter of 2023 was $0.10, compared to $0.45 in the prior year period. GAAP operating income for the fourth quarter of 2023 was $40 million, compared to $87 million in the prior year period, and GAAP operating margin was 5% in the fourth quarter of 2023, compared to 10% in the prior year period. Fourth quarter 2023 results included $33 million in integration-related charges.

Adjusted diluted EPS for the fourth quarter of 2023 was $1.17, compared to $1.76 in the prior year period. Adjusted EBITDA for the fourth quarter of 2023 was $195 million, compared to $245 million in the prior year period. Adjusted EBITDA margin for the fourth quarter of 2023 was 26%, compared to 28% in the prior year period. The year-over-year change in adjusted diluted EPS and adjusted EBITDA was primarily related to the decline in COVID-19 revenue compared to the prior year period, as anticipated.

Full-Year 2023

The Company reported total revenue for the full-year 2023 of $3.0 billion, compared to $3.3 billion in the prior year. Foreign currency translation did not significantly impact full-year 2023 results. GAAP diluted loss per share for the full-year 2023 was $0.15, compared to diluted EPS of $9.56 in the prior year. GAAP operating income for the full-year 2023 was $139 million, compared to $844 million in the prior year, and GAAP operating margin was 5% for the full-year 2023, compared to 26% in the prior year. Full-year 2023 results included $113 million in integration-related charges.

To facilitate a year-over-year comparison of the Company’s operating performance, all growth rates referenced below are presented on a supplemental combined basis as if Quidel Corporation and Ortho Clinical Diagnostics Holdings plc had been combined for the full-year 2022 and are referred to as “supplemental combined” information.

Adjusted diluted EPS for the full-year 2023 was $4.13, compared to supplemental combined adjusted diluted EPS of $13.80 in the prior year. Adjusted EBITDA for the full-year 2023 was $723 million, compared to supplemental combined adjusted EBITDA of $1.54 billion in the prior year. Adjusted EBITDA margin for the full-year 2023 was 24%, compared to supplemental combined adjusted EBITDA margin of 38% in the prior year. The year-over-year change in adjusted EPS and adjusted EBITDA was primarily related to the anticipated decline in COVID-19 revenue compared to the prior year.

Fiscal Year 2024 Financial Guidance

Based on its current business outlook, the Company is providing fiscal year 2024 financial guidance, as follows:
Total revenues (reported)
$2.76 - $3.07 billion
Non-respiratory revenue
$2.30 - $2.34 billion
Respiratory revenue
$460 - $730 million
Adjusted EBITDA
$565 - $720 million
Adjusted EBITDA %
21% - 24%
Adjusted diluted EPS
$2.40 - $3.07
Please see Slide 9 of the QuidelOrtho Q4-FY23 earnings presentation for more information about 2024 financial guidance assumptions.










qographic.jpg
Conference Call Information

QuidelOrtho will hold a conference call today at 2:00 p.m. PT / 5:00 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023. Interested parties can access the call on the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at https://ir.quidelortho.com/. Presentation materials will also be posted to the “Events & Presentations” section of the “Investor Relations” page of the Company’s website at the time of the call. Those unable to access the webcast may join the call via phone by dialing 833-470-1428 (domestic) or 929-526-1599 (international) and entering Conference ID number 437438.

A replay of the conference call will be available shortly after the event on the “Investor Relations” page of the Company’s website, under the “Events & Presentations” section.

About QuidelOrtho Corporation

QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.

Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.

Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.

QuidelOrtho is advancing diagnostics to power a healthier future.

For more information, please visit www.quidelortho.com.
Source: QuidelOrtho Corporation



qographic.jpg
Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are any statement contained herein that is not strictly historical, including, but not limited to, QuidelOrtho’s commercial, integration, transformation and other strategic goals, financial guidance and other future financial condition and operating results, and future plans, objectives, strategies, expectations and intentions. Without limiting the foregoing, the words “may,” “will,” “would,” “should,” “might,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “goal,” “project,” “strategy,” “future,” “continue” or similar words, expressions or the negative of such terms or other comparable terminology are intended to identify forward-looking statements. Such statements are based on the beliefs and expectations of QuidelOrtho’s management as of today and are subject to significant known and unknown risks and uncertainties. Actual results or outcomes may differ significantly from those set forth or implied in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth or implied in the forward-looking statements: supply chain, production, logistics, distribution and labor disruptions and challenges; the challenges and costs of integrating, restructuring and achieving anticipated synergies as a result of the business combination (the “Combinations”) of Quidel Corporation (“Quidel”) and Ortho Clinical Diagnostics Holdings plc (“Ortho”); and other macroeconomic, geopolitical, market, business, competitive and/or regulatory factors affecting the business of QuidelOrtho generally, including those discussed under Part I, Item 1A, “Risk Factors” of QuidelOrtho’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023 and subsequent reports filed with the Securities and Exchange Commission (the “Commission”). You should not rely on forward-looking statements as predictions of future events because these statements are based on assumptions that may not come true and are speculative by their nature. All forward-looking statements are based on information currently available to QuidelOrtho and speak only as of the date hereof. QuidelOrtho undertakes no obligation to update any of the forward-looking information or time-sensitive information included in this press release, whether as a result of new information, future events, changed expectations or otherwise, except as required by law.

Supplemental Combined Financial Measures

This press release contains unaudited supplemental combined financial information (“Supplemental Combined Information”) that gives effect to the Combinations as if Quidel and Ortho had been combined for the applicable periods. Certain Supplemental Combined Information presented is based on the historical financial statements of Quidel and Ortho with reclassification adjustments only and do not include all of the pro forma adjustments required under Regulation S-X Article 11 or Accounting Standards Codification 805, Business Combinations (“ASC 805”). The Supplemental Combined Information is provided for illustrative purposes only, may be updated in the future, and is not necessarily, and should not be assumed to be, indicative of the Company’s expected results of operations or financial position that would have been achieved had the Combinations been completed as of the dates indicated or that may be achieved in any future period. The Supplemental Combined Information should be considered supplemental to, and not as a substitute for, pro forma financial information prepared in accordance with Regulation S-X Article 11 or ASC 805 and should be read in conjunction with the information contained in the sections entitled “The Combinations,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Ortho” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations of Quidel” in QuidelOrtho’s joint proxy statement/prospectus (the “Joint Proxy Statement/Prospectus”) filed with the Commission on April 11, 2022 and the historical consolidated financial statements and related notes appearing elsewhere in, or incorporated into, the Joint Proxy Statement/Prospectus, and the Company’s subsequent reports filed with the Commission. The Company’s actual results of operations and financial position will differ, potentially significantly, from the Supplemental Combined Information reflected in this press release as a result of the methodology used to prepare the Supplemental Combined Information as well as a variety of factors, including but not limited to the effect of certain expected financial benefits of the Combinations (such as revenue and cost synergies), the anticipated costs to achieve these benefits (including the cost of integration activities), tax impacts, and changes in operating results following the date of this press release.



qographic.jpg
Non-GAAP Financial Measures

This press release contains financial measures, including but not limited to “constant currency” revenue changes, “adjusted net income,” “adjusted diluted EPS,” “adjusted EBITDA,” “adjusted EBITDA margin,” “adjusted free cash flow,” “supplemental combined adjusted net income,” “supplemental combined adjusted diluted EPS,” “supplemental combined adjusted EBITDA,” “supplemental combined adjusted EBITDA margin” and “supplemental combined revenues by business unit and region,” which are considered non-GAAP financial measures under applicable rules and regulations of the Commission. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, financial information prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). “Adjusted net income,” “adjusted diluted EPS,” “adjusted EBITDA,” “adjusted EBITDA margin” and “adjusted free cash flow” eliminate impacts of certain non-cash, unusual or other items that the Company does not consider indicative of its ongoing operating performance, and the Company generally uses these non-GAAP financial measures to facilitate management’s financial and operational decision-making, including evaluation of the Company’s historical operating results and comparison to competitors’ operating results. The Company believes that “supplemental combined adjusted net income,” “supplemental combined adjusted diluted EPS,” “supplemental combined adjusted EBITDA,” “supplemental combined adjusted EBITDA margin” and “supplemental combined revenues by business unit and region” provide helpful Supplemental Combined Information to assist management and investors in evaluating the Company’s adjusted operating results as if Quidel and Ortho had been combined for the applicable periods. The Company’s definitions of these non-GAAP measures may differ from similarly titled measures used by others. These non-GAAP financial measures reflect an additional way of viewing aspects of the Company’s operations that, when viewed with GAAP results and the reconciliations to corresponding GAAP financial measures, may provide a more complete understanding of factors and trends affecting the Company’s business. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, management strongly encourages investors to review the Company’s consolidated financial statements and reports filed with the Commission in their entirety. Reconciliations of the non-GAAP financial measures, including the non-GAAP Supplemental Combined Information, to the most directly comparable GAAP financial measures are included in the tables accompanying this press release.

Investor Contact:
Juliet Cunningham
Vice President, Investor Relations
IR@quidelortho.com

Media Contact:
Stephanie Kleewein
Communications Manager
media@quidelortho.com


qographic.jpg

QuidelOrtho
Consolidated Statements of Operations
(Unaudited)
(In millions except per share data)

 Three Months EndedFiscal Year Ended
 
December 31, 2023 (a)
January 1, 2023 (b)
December 31, 2023 (a)
January 1, 2023 (b)
Total revenues$742.6 $866.5 $2,997.8 $3,266.0 
Cost of sales, excluding amortization of intangibles361.3 417.5 1,503.4 1,330.0 
Selling, marketing and administrative187.6 213.6 763.2 621.0 
Research and development59.3 64.3 246.8 190.5 
Amortization of intangible assets51.2 53.9 204.8 132.5 
Acquisition and integration costs33.0 26.4 113.4 136.0 
Other operating expenses10.1 4.3 27.1 12.3 
Operating income
40.1 86.5 139.1 843.7 
Interest expense, net36.7 34.7 147.6 75.7 
Loss on extinguishment of debt— — — 24.0 
Other expense, net12.6 10.7 20.6 8.1 
(Loss) income before provision for income taxes(9.2)41.1 (29.1)735.9 
(Benefit from) provision for income taxes(16.2)10.8 (19.0)187.2 
Net income (loss)
$7.0 $30.3 $(10.1)$548.7 
Basic earnings (loss) per share
$0.10 $0.46 $(0.15)$9.66 
Diluted earnings (loss) per share
$0.10 $0.45 $(0.15)$9.56 
Weighted-average shares outstanding - basic66.9 66.3 66.8 56.8 
Weighted-average shares outstanding - diluted67.3 66.9 66.8 57.4 
(a) Includes Ortho results of operations for the three months ended and fiscal year ended December 31, 2023.
(b) Includes Ortho results of operations for the three months ended January 1, 2023 and from May 27, 2022 through January 1, 2023 for the fiscal year ended January 1, 2023.


qographic.jpg

QuidelOrtho
Condensed Consolidated Balance Sheets
(Unaudited)
(In millions)

December 31, 2023January 1, 2023
Cash and cash equivalents$118.9 $292.9 
Marketable securities48.4 52.1 
Accounts receivable, net303.3 453.9 
Inventories577.8 524.1 
Prepaid expenses and other current assets262.1 252.1 
Property, plant and equipment, net1,443.8 1,339.0 
Marketable securities7.4 21.0 
Right-of-use assets169.6 181.0 
Goodwill2,492.0 2,476.8 
Intangible assets, net2,934.3 3,123.8 
Deferred tax asset25.9 16.4 
Other assets179.6 122.7 
Total assets$8,563.1 $8,855.8 
Accounts payable$294.8 $283.3 
Accrued payroll and related expenses84.8 139.2 
Income tax payable11.1 51.6 
Current portion of borrowings139.8 207.5 
Other current liabilities303.3 325.4 
Operating lease liabilities172.8 186.4 
Long-term borrowings2,274.8 2,430.8 
Deferred tax liability192.2 213.2 
Other liabilities83.6 83.8 
Total liabilities3,557.2 3,921.2 
Total stockholders’ equity5,005.9 4,934.6 
Total liabilities and stockholders’ equity$8,563.1 $8,855.8 




qographic.jpg

QuidelOrtho
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In millions)

Fiscal Year Ended
December 31, 2023 (a)
January 1, 2023 (b)
Cash provided by operating activities$280.2 $885.3 
Cash used for investing activities(187.6)(1,644.2)
Cash (used for) provided by financing activities(265.8)252.0 
Effect of exchange rate changes on cash(1.2)(2.0)
Net decrease in cash, cash equivalents and restricted cash(174.4)(508.9)
Cash, cash equivalents and restricted cash at beginning of period293.9 802.8 
Cash, cash equivalents and restricted cash at end of period$119.5 $293.9 
Reconciliation to amounts within the consolidated balance sheets:
Cash and cash equivalents$118.9 $292.9 
Restricted cash in Other assets0.6 1.0 
Cash, cash equivalents and restricted cash$119.5 $293.9 

(a) Includes Ortho activities for the fiscal year ended December 31, 2023.
(b) Includes Ortho activities from May 27, 2022 through January 1, 2023.


qographic.jpg

QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted Net Income
(In millions, except per share data; unaudited)

Three Months EndedFiscal Year Ended
December 31, 2023 (a)
Diluted EPS
January 1, 2023 (b)
Diluted EPS
December 31, 2023 (a)
Diluted EPS
January 1, 2023 (b)
Diluted EPS
Net income (loss)
$7.0 $0.10 $30.3 $0.45 $(10.1)$(0.15)$548.7 $9.56 
Adjustments:
Amortization of intangibles51.2 53.9 204.8 132.5 
Acquisition and integration costs33.0 26.4 113.4 136.0 
Tax indemnification expense12.8 — 12.6 — 
Incremental depreciation on PP&E fair value
   adjustment
8.2 9.2 33.5 10.5 
Amortization of deferred cloud computing
    implementation costs
3.3 1.5 9.2 5.4 
Loss on investments2.4 5.0 3.6 5.8 
Impairment of long-lived assets1.3 2.8 4.5 2.8 
EU medical device regulation transition costs0.6 0.5 2.5 1.5 
Unwind inventory fair value adjustment— 14.0 — 60.6 
Employee compensation charges— 1.7 — 3.2 
Noncash interest expense for deferred
    consideration
— 0.6 0.7 2.9 
Loss on extinguishment of debt— — — 24.0 
Derivative mark-to-market gain— — — (4.4)
Other adjustments(0.9)0.2 1.7 0.6 
Income tax impact of adjustments(30.0)(30.3)(87.5)(76.8)
Discrete tax items(10.3)1.8 (11.2)2.4 
Adjusted net income$78.6 $1.17 $117.6 $1.76 $277.7 $4.13 $855.7 $14.91 
Ortho pre-combination adjusted net income— — — 77.2 
Supplemental combined adjusted net income$78.6 $1.17 $117.6 $1.76 $277.7 $4.13 $932.9 $13.80 
Weighted-average shares outstanding - diluted67.3 66.9 67.3 57.4 
Weighted-average shares outstanding - diluted -
     supplemental combined
67.3 66.9 67.3 67.6 
(a) Adjusted net income includes Ortho activities for the three months ended and fiscal year ended December 31, 2023.
(b) Adjusted net income includes Ortho activities for the three months ended January 1, 2023 and from May 27, 2022 through January 1, 2023 for the fiscal year ended January 1, 2023.


qographic.jpg


QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted EBITDA
(In millions, unaudited)

Three Months EndedFiscal Year Ended
December 31, 2023 (a)
January 1, 2023 (b)
December 31, 2023 (a)
January 1, 2023 (b)
Net income (loss)$7.0 $30.3 $(10.1)$548.7 
Depreciation and amortization115.4 116.6 457.2 283.6 
Interest expense, net36.7 34.7 147.6 75.7 
(Benefit from) provision for income taxes(16.2)10.8 (19.0)187.2 
Acquisition and integration costs33.0 26.4 113.4 136.0 
Tax indemnification expense12.8 0.6 12.6 0.3 
Amortization of deferred cloud computing
    implementation costs
3.3 1.5 9.2 5.4 
Loss on investments2.4 5.0 3.6 5.8 
Impairment of long-lived assets1.3 2.8 4.5 2.8 
EU medical device regulation transition costs0.6 0.5 2.5 1.5 
Unwind inventory fair value adjustment— 14.0 — 60.6 
Employee compensation charges— 1.7 — 3.2 
Loss on extinguishment of debt— — — 24.0 
Derivative mark-to-market gain— — — (4.4)
Other adjustments(0.9)0.2 1.7 0.6 
Adjusted EBITDA$195.4 $245.1 $723.2 $1,331.0 
Ortho pre-combination Adjusted EBITDA— — — 212.5 
Supplemental combined Adjusted EBITDA$195.4 $245.1 $723.2 $1,543.5 

(a) Adjusted EBITDA includes Ortho activities for the three months ended and fiscal year ended December 31, 2023.
(b) Adjusted EBITDA includes Ortho activities for the three months ended January 1, 2023 and from May 27, 2022 through January 1, 2023 for the fiscal year ended January 1, 2023.


qographic.jpg

QuidelOrtho
Supplemental Combined Revenues by Business Unit and Region
(In millions, unaudited)

Three Months Ended
December 31, 2023January 1, 2023% ChangeCurrency Impact
Constant Currency (a)
Respiratory revenues$174.6 $344.0 (49.2)%0.1 %(49.3)%
Non-Respiratory revenues568.0 522.5 8.7 %(0.3)%9.0 %
Total revenues$742.6 $866.5 (14.3)%— %(14.3)%

Three Months Ended
December 31, 2023January 1, 2023% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
Labs$351.9 $314.7 11.8 %(0.5)%12.3 %(1.0)%13.3 %
Transfusion Medicine165.4 162.5 1.8 %(0.4)%2.2 %— %2.2 %
Point of Care216.8 374.7 (42.1)%0.1 %(42.2)%(48.2)%6.0 %
Molecular Diagnostics8.5 14.6 (41.8)%— %(41.8)%(31.3)%(10.5)%
Total revenues$742.6 $866.5 (14.3)%— %(14.3)%(23.3)%9.0 %

Three Months Ended
December 31, 2023January 1, 2023% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
North America$450.3 $619.2 (27.3)%(0.5)%(26.8)%(26.7)%(0.1)%
EMEA90.9 75.8 19.9 %1.8 %18.1 %(4.9)%23.0 %
China77.1 56.9 35.5 %(2.4)%37.9 %0.7 %37.2 %
Other124.3 114.6 8.5 %1.6 %6.9 %(3.4)%10.3 %
Total revenues$742.6 $866.5 (14.3)%— %(14.3)%(23.3)%9.0 %

(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.


qographic.jpg

Fiscal Year Ended
December 31, 2023January 1, 2023% ChangeCurrency Impact
Constant Currency (a)
Respiratory revenues$714.6 $1,866.5 (61.7)%— %(61.7)%
Non-Respiratory revenues2,283.2 2,184.7 4.5 %(0.9)%5.4 %
Total supplemental combined revenues (b)
$2,997.8 $4,051.2 (26.0)%(0.1)%(25.9)%

Fiscal Year Ended
December 31, 2023January 1, 2023% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
Labs (b)
$1,425.4 $1,331.2 7.1 %(1.0)%8.1 %(1.9)%10.0 %
Transfusion Medicine648.5 668.1 (2.9)%(0.9)%(2.0)%— %(2.0)%
Point of Care892.2 1,955.2 (54.4)%(0.1)%(54.3)%(56.1)%1.8 %
Molecular Diagnostics31.7 96.7 (67.2)%0.1 %(67.3)%(54.0)%(13.3)%
Total supplemental combined revenues (b)
$2,997.8 $4,051.2 (26.0)%(0.1)%(25.9)%(31.3)%5.4 %

Fiscal Year Ended
December 31, 2023January 1, 2023% ChangeCurrency Impact
Constant Currency (a)
Respiratory Revenue Impact
Constant Currency (a)
Non-Respiratory Revenue
North America$1,877.1 $2,970.3 (36.8)%(0.3)%(36.5)%(37.0)%0.5 %
EMEA327.3 316.4 3.4 %0.1 %3.3 %(4.8)%8.1 %
China310.1 297.1 4.4 %(4.4)%8.8 %(12.1)%20.9 %
Other483.3 467.4 3.4 %— %3.4 %(5.3)%8.7 %
Total supplemental combined revenues (b)
$2,997.8 $4,051.2 (26.0)%(0.1)%(25.9)%(31.3)%5.4 %

Supplemental combined revenues for the prior period in the tables above include Ortho revenues as if the acquisition had occurred on January 2, 2022.
(a) The term “constant currency” means we have translated local currency revenues for all reporting periods to U.S. dollars using currency exchange rates held constant for each period. This additional non-GAAP financial information is not meant to be considered in isolation from or as a substitute for financial information prepared in accordance with GAAP.
(b) The fiscal year ended December 31, 2023 includes an approximate $19 million settlement award from a third party related to one of the Company’s collaboration agreements.


qographic.jpg
QuidelOrtho
Reconciliation of Non-GAAP Financial Information - Adjusted Free Cash Flow
(In millions, unaudited)

Three Months Ended
Fiscal Year Ended
December 31, 2023December 31, 2023
Net cash provided by operating activities$80.4 $280.2 
Adjustments:
Capital expenditures(45.1)(191.4)
Other payments (a)
53.3 180.8 
Adjusted free cash flow $88.6 $269.6 

(a) For the three months ended December 31, 2023, other payments include $29 million related to acquisition, integration and other costs, $17 million of integration-related cloud computing implementation costs and $7 million of other integration-related capital expenditures. For the fiscal year ended December 31, 2023, other payments include $116 million related to acquisition, integration and other costs, $47 million of integration-related cloud computing implementation costs and $18 million of other integration-related capital expenditures.

EX-101.SCH 3 qdel-20240213.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information Document link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 qdel-20240213_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 qdel-20240213_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Address Type [Domain] Address Type [Domain] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover page. Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 qdel-20240213_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 qographic.jpg begin 644 qographic.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Document and Entity Information Document
Feb. 13, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Feb. 13, 2024
Entity Incorporation, State or Country Code DE
Entity File Number 001-41409
Entity Tax Identification Number 87-4496285
Entity Address, Address Line One 9975 Summers Ridge Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 552-1100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 Par Value
Trading Symbol QDEL
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001906324
Amendment Flag false
Entity Registrant Name QUIDELORTHO CORP
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

35@<.&7J/P$ #P" / " 500 !X;"]W;W)K8F]O M:RYX;6Q02P$"% ,4 " #G@$U8)!Z;HJT #X 0 &@ M@ ' $0 >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #G M@$U899!YDAD! #/ P $P @ &E$@ 6T-O;G1E;G1?5'EP =97-=+GAM;%!+!08 "0 ) #X" #O$P ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Document Sheet http://www.quidel.com/role/DocumentandEntityInformationDocument Document and Entity Information Document Cover 1 false false All Reports Book All Reports qdel-20240213.htm qdel-20240213.xsd qdel-20240213_def.xml qdel-20240213_lab.xml qdel-20240213_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "qdel-20240213.htm": { "nsprefix": "qdel", "nsuri": "http://www.quidel.com/20240213", "dts": { "inline": { "local": [ "qdel-20240213.htm" ] }, "schema": { "local": [ "qdel-20240213.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "qdel-20240213_def.xml" ] }, "labelLink": { "local": [ "qdel-20240213_lab.xml" ] }, "presentationLink": { "local": [ "qdel-20240213_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 27, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.quidel.com/role/DocumentandEntityInformationDocument", "longName": "0000001 - Document - Document and Entity Information Document", "shortName": "Document and Entity Information Document", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "qdel-20240213.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "qdel-20240213.htm", "first": true, "unique": true } } }, "tag": { "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AddressTypeDomain", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Address Type [Domain]", "label": "Address Type [Domain]", "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Addresses, Address Type [Axis]", "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.quidel.com/role/DocumentandEntityInformationDocument" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001906324-24-000002-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001906324-24-000002-xbrl.zip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�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qdel-20240213_htm.xml IDEA: XBRL DOCUMENT 0001906324 2024-02-13 2024-02-13 0001906324 false 8-K 2024-02-13 QUIDELORTHO CORP DE 001-41409 87-4496285 9975 Summers Ridge Road San Diego CA 92121 858 552-1100 false false false false Common Stock, $0.001 Par Value QDEL NASDAQ false